Skip to content

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
+0.5×
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
0.0×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
0.7×-0.4×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
0.0×
Janux Therapeutics logo
Janux TherapeuticsJANX
0.0×

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Calculated from TuHURA Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s debt-to-assets?
TuHURA Biosciences, Inc. (HURA) reported debt-to-assets of 0× in Q1 2026.
How has TuHURA Biosciences, Inc.'s debt-to-assets changed year-over-year?
TuHURA Biosciences, Inc.'s debt-to-assets increased by 37.5% year-over-year, from 0× to 0×.
What is the long-term trend for TuHURA Biosciences, Inc.'s debt-to-assets?
Over 2 years (2023 to 2025), TuHURA Biosciences, Inc.'s debt-to-assets has grown at a 95.8% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.